trial

Tryptophan MRI in People With Schizophrenia and Healthy Controls

NCTId NCT02067975
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 93 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2019-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
93 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2014-08-14
Primary completion
2019-12-31
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Tryptophan

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
Tanabe Pharma CorporationCollaborator
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Robert C Smith, M.D., Ph.DPrincipal Investigator

Sites

1 total
Catonsville, United States

Linked catalysts

1
Tryptophan MRI in People With Schizophrenia and Healthy Controls — primary completion2019-12-31

Facts & assertions

4 sourced
Enrollment
93
Phase
PHASE2,PHASE3
Primary Completion Date
2019-12-31
Status
COMPLETED
relationships
The graph out of here
drug
Tryptophan
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
Tanabe Pharma Corporation
company
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert C Smith, M.D., Ph.D
person